MoonLake Immunotherapeutics (MLTX) EBIT (QoQ) (2021 - 2026)
Powered by 
Analysis
MoonLake Immunotherapeutics (MLTX) EBIT (QoQ) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn |
| 10 | MoonLake Immunotherapeutics | 1.10 Bn | 566.16 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 11.94% |
| Mar 31, 2026 | -7.37% |
| Dec 31, 2025 | 8.70% |
| Sep 30, 2025 | -17.69% |
| Jun 30, 2025 | -27.83% |
| Mar 31, 2025 | 4.23% |
| Dec 31, 2024 | -15.00% |
| Sep 30, 2024 | -40.99% |
| Jun 30, 2024 | -54.28% |
| Mar 31, 2024 | -31.88% |
| Dec 31, 2023 | -15.81% |
| Sep 30, 2023 | 1.59% |
| Jun 30, 2023 | -1.97% |
| Mar 31, 2023 | 22.55% |
| Dec 31, 2022 | -13.04% |
| Sep 30, 2022 | 16.32% |
| Jun 30, 2022 | -10.73% |
| Mar 31, 2022 | 70.24% |
| Dec 31, 2021 | -754.88% |
| Sep 30, 2021 | 80.82% |